Analyst UpgradeAnalyst upgrades CVS from Neutral to Buy, following two strong consecutive quarters of execution and early signs that the Healthcare Benefits (HCB) segment fixes are on track.
Contract WinsCVS Caremark wins contract from OptumRx, providing outpatient prescription drug benefits for approximately 587K members enrolled in Basic or Medicare HMO and PPO plans.
Earnings GrowthCVS is projected to return to a mid-3x leverage ratio by a future quarter, allowing for earnings growth via buybacks.